NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.
Lonza Group ( VTX:LONN ) Full Year 2023 Results Key Financial Results Revenue: CHF6.72b (up 7.9% from FY 2022). Net...
Key Insights The considerable ownership by individual investors in Lonza Group indicates that they collectively have a...